MedTrace Logo

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

NCT00568308 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2011-06-15

No results posted yet for this study

Summary

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Conditions

Interventions

DRUG

PI-88

160mg subcutaneous injection

DRUG

placebo

matched placebo

Sponsors & Collaborators

  • Progen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ronnie TP Poon, MD · University of Hong Kong, Queen Mary Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States
  • Australia
  • Canada
  • Hong Kong
  • Italy
  • Malaysia
  • Singapore
  • Spain
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568308 on ClinicalTrials.gov